Key Takeaways
- Azitra (AZTR) shares climbed as high as 87% during Friday’s session following a private placement announcement
- The company secured $10.5 million upfront via preferred stock, with potential total proceeds reaching $31.4 million through warrant exercises
- Participants in the funding round include Stonepine Capital, Nantahala Capital, healthcare sector professionals, and the company’s CEO
- Funds will support the development of filaggrin-based proteins and peptides targeting the cosmetic industry
- The company faces a delisting notice from NYSE American related to equity requirements, with shares down over 91% across the past year
Azitra (AZTR) shares experienced a dramatic rally of up to 87% during Friday’s trading session after the biotech firm disclosed terms of a private placement transaction capable of generating up to $31.4 million in total proceeds.
The transaction reached closing on or near Friday, subject to standard closing conditions. This surge followed a 28.82% gain recorded the previous trading day when the placement was initially disclosed to the market.
The capital raise consists of two distinct components. The company immediately secured $10.5 million through issuing 10,470 shares of Series A convertible non-redeemable preferred stock, priced at $1,000 per share.
The additional $20.9 million hinges on the cash exercise of Series B and Series C warrants. Each warrant series grants holders the right to acquire up to 85,101,201 common shares at an exercise price of $0.123 per share.
Each preferred share undergoes automatic conversion into approximately 8,129 common shares following stockholder approval. Series B Warrants carry an 18-month expiration period following that approval milestone. Series C Warrants expire 30 days after the company releases results from a planned human cosmetic study.
Trading activity surged dramatically following the announcement. Over 166 million AZTR shares traded hands on Friday, dwarfing the three-month daily average of approximately 170,000 shares.
Intended Use of Capital
Azitra intends to allocate the raised capital toward developing proteins and peptides designed for the consumer cosmeceutical sector, emphasizing filaggrin-based technology. The company employs a microbial genetic engineering platform for this development work.
Additional allocations include general corporate expenses, research and development initiatives, and working capital needs.
The investor group includes Stonepine Capital, Nantahala Capital, additional institutional healthcare investment funds, medical professionals, and company insiders — particularly the Chief Executive Officer.
Financial Situation Overview
The company’s stock performance presents a challenging picture. AZTR traded around $0.14 before this rally, representing approximately a 94% decline over the trailing twelve months. The company’s market capitalization stood at merely $2.21 million.
Cash consumption remains elevated, with levered free cash flow reaching negative $10.93 million across the past twelve months. The company maintains a positive balance between cash and debt, alongside a current ratio of 2.83.
AZTR currently operates under a delisting warning issued by NYSE American. The exchange cited non-compliance with Section 1003(a)(iii), which mandates minimum stockholders’ equity of $6 million for companies reporting losses from continuing operations across five fiscal years.
Resolving this compliance issue remains necessary to maintain the company’s exchange listing.
Regarding analyst coverage, Jason McCarthy of Maxim Group provides the sole coverage of AZTR, maintaining a Buy rating alongside a $1 price target.
Through the current year, AZTR shares remain down 33.3%.
